author-photo

Kathleen Turnbull

Pfizer

27

Papers

1034

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Myeloproliferative Neoplasm Symptom Assessment Diary

2021
Show All
- Source
- Cite
- Save
Citations (0)
Development of a symptom assessment in patients with myelofibrosis: qualitative study findings

2019 Health and Quality of Life Outcomes
Show All
- Source
- Cite
- Save
Citations (1)
Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

2015 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (53)
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up: Bosutinib in Imatinib-treated CP CML: 24 Months

2014 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance

2014 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer

2014 Oncologist
Show All
- Source
- Cite
- Save
Citations (18)
Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (161)
Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer

2014 Oncologist
Show All
- Source
- Cite
- Save
Citations (11)
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

2014 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (76)